U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT03394781) titled 'A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)' on Jan. 3, 2018.
Brief Summary: This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).
Study Type: Interventional
Condition: Primary Sclerosing Cholangitis
Intervention: Drug: DUR-928
oral suspension daily for 28 days
Recruitment Status: Recruiting
Sponsor: Durect
Information provided by (Responsible Party):...